ABBVIE
Observational Study Evaluating the Effectiveness of Drug Concentration to Predict the Recapture of Response in Crohn's Disease Patients With Loss of Response ( PRADA )
- Conditions
- Crohn's Disease
- First Posted Date
- 2016-09-12
- Last Posted Date
- 2021-03-09
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 98
- Registration Number
- NCT02896985
- Locations
- 🇨🇦
Columbia Gastro Mgmnt Ltd /ID# 152507, New Westminster, British Columbia, Canada
🇨🇦GIRI Gastrointestinal Research Institute /ID# 201259, Vancouver, British Columbia, Canada
🇨🇦Percuro Clinical Research, Ltd /ID# 202502, Victoria, British Columbia, Canada
Canadian Humira Post Marketing Observational Epidemiological Study : Assessing Humira Real-life Effectiveness and Impact on HS Burden of Illness
- Conditions
- Hidradenitis Suppurativa (HS)
- First Posted Date
- 2016-09-12
- Last Posted Date
- 2020-05-01
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 165
- Registration Number
- NCT02896920
- Locations
- 🇨🇦
Alberta DermaSurgery Centre /ID# 153834, Edmonton, Alberta, Canada
🇨🇦Institute for Skin Advancement /ID# 152448, Calgary, Alberta, Canada
🇨🇦Dre. Angelique Gagne-Henley /ID# 152611, St-Jerome, Quebec, Canada
A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Participants With Early Alzheimer's Disease
- Conditions
- Alzheimer's Disease
- Interventions
- Drug: ABBV-8E12Drug: placebo for ABBV-8E12
- First Posted Date
- 2016-08-26
- Last Posted Date
- 2022-08-26
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 453
- Registration Number
- NCT02880956
- Locations
- 🇺🇸
Irvine Clinical Research /ID# 162331, Irvine, California, United States
🇺🇸Brain Matters Research /ID# 147796, Delray Beach, Florida, United States
🇺🇸Neuropsychiatric Research Center of Southwest Florida /ID# 162332, Fort Myers, Florida, United States
Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Colombia
- Conditions
- Chronic Hepatitis C
- First Posted Date
- 2016-08-01
- Last Posted Date
- 2019-09-18
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 66
- Registration Number
- NCT02851069
- Locations
- 🇨🇴
Centro Medico lmbanaco de Cali I, Cali, Colombia
🇨🇴Fundacion Hospitalaria San Vin, Medellín, Colombia
🇨🇴Cic Cali, Cali, Colombia
A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Extensive Stage Small Cell Lung Cancer
- Conditions
- Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2016-06-30
- Last Posted Date
- 2020-03-12
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 28
- Registration Number
- NCT02819999
- Locations
- 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸University Hospital of Cleveland, Cleveland, Ohio, United States
🇺🇸Rocky Mountain Cancer Centers, Denver, Colorado, United States
A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
- First Posted Date
- 2016-06-30
- Last Posted Date
- 2022-06-30
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 1302
- Registration Number
- NCT02819635
- Locations
- 🇺🇸
The Vancouver Clinic, INC. PS /ID# 162333, Vancouver, Washington, United States
🇺🇸East View Medical Research, LLC /ID# 171183, Mobile, Alabama, United States
🇺🇸CB Flock Research Corporation /ID# 165980, Mobile, Alabama, United States
Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin and Patient Support Program in Patients With Chronic Hepatitis C
- Conditions
- Chronic Hepatitis C
- First Posted Date
- 2016-06-29
- Last Posted Date
- 2019-05-17
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 51
- Registration Number
- NCT02817594
- Locations
- 🇳🇱
Noordwest Ziekenhuisgroep /ID# 152604, Alkmaar, Netherlands
🇳🇱Maasstad Ziekenhuis /ID# 152592, Rotterdam, Netherlands
🇳🇱Universitair Medisch Centrum Groningen /ID# 152596, Groningen, Netherlands
Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA
- Conditions
- Bacterial InfectionsMethicillin-Resistant Staphylococcus AureusStaphylococcal Skin Infections
- Interventions
- First Posted Date
- 2016-06-28
- Last Posted Date
- 2024-01-17
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 199
- Registration Number
- NCT02814916
- Locations
- 🇱🇹
Klaipeda Children's Hospital /ID# 235652, Klaipeda, Lithuania
🇧🇬University Multiprofile Hospital for Active Treatment Deva Maria EOOD Burgas /ID# 235965, Bulgas, Bulgaria
🇧🇬MHAT (Multiprofile Hospital for Active Treatment) /ID# 235539, Kozloduy, Bulgaria
A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL)
- Conditions
- Psoriatic Arthritis
- Interventions
- Drug: methotrexate (MTX)Biological: adalimumab (ADA)
- First Posted Date
- 2016-06-27
- Last Posted Date
- 2020-11-23
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 246
- Registration Number
- NCT02814175
- Locations
- 🇺🇸
Ochsner Clinic Foundation /ID# 155178, Baton Rouge, Louisiana, United States
🇨🇴Centro de Investigacion en Reumatologia y Especialidades Medicas- CIREEM SAS /ID# 151954, Bogota, Cundinamarca, Colombia
🇵🇷Dr. Ramon L. Ortega-Colon, MD /ID# 152957, Carolina, Puerto Rico
Safety and Efficacy of Adalimumab (Humira) for Hidradenitis Suppurativa (HS) Peri-Surgically
- First Posted Date
- 2016-06-22
- Last Posted Date
- 2020-05-14
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 206
- Registration Number
- NCT02808975
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center /ID# 168438, Boston, Massachusetts, United States
🇧🇪UZ Gent /ID# 150906, Gent, Oost-Vlaanderen, Belgium
🇨🇦NewLab Clinical Research Inc. /ID# 151315, St. John's, Newfoundland and Labrador, Canada